⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403868 | 0.79 | — | — | |
| SCHEMBL30503583 | 0.79 | — | — | |
| SCHEMBL29896652 | 0.74 | — | — | |
| SCHEMBL876343 | 0.74 | — | — | |
| SCHEMBL7111811 | 0.74 | — | — | |
| SCHEMBL414351 | 0.74 | — | — | |
| SCHEMBL31452225 | 0.74 | — | — | |
| SCHEMBL1828211 | 0.74 | — | — | |
| SCHEMBL156190 | 0.74 | — | — | |
| SCHEMBL18562235 | 0.71 | GLP1R (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090317-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| CN-119707930-A | Aromatic ring compound and its prepn and use | 甘李药业股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-3492461-B1 | NITROGENOUS HETEROCYCLIC AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF | SHANGHAI YINGLI PHARM CO LTD (CN) | 2024-10-23 | — | — | EP | disclosed |
| US-20240294495-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-05 | — | — | US | disclosed |
| US-11939349-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2024-03-26 | — | — | US | disclosed |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| EP-3340983-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-4214199-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-07-26 | — | — | EP | disclosed |
| CN-116490503-A | Casein kinase 1 delta modulators | 詹森药业有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20150065464-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2015-03-05 | — | — | US | disclosed |
| WO-2014201206-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| US-20140371201-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2014-12-18 | — | — | US | disclosed |
| EP-2758375-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | Advinus Therapeutics Limited (IN) | 2014-07-30 | — | — | EP | disclosed |
| EP-1971595-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2013042139-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-03-28 | — | — | WO | disclosed |
| US-7910592-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090042892-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-02-12 | — | — | US | disclosed |
| EP-1971595-A2 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007081569-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |